Teratogenic effects of epilepsy and anti-epileptic drugs;Efectos teratógenos de la epilepsia y de los fármacos antiepilépticos

Revista de Neurologia

Volumn 35, Issue SUPPL. 1, 2002, Pages

  Campistol, Jaume ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL SANT JOAN DE DÉU   (Spain)

Author keywords

Epilepsy; EURAP; Guidelines for treatment; New anti epileptic drugs; Pregnancy; Teratogenicity

Indexed keywords

4 AMINOBUTYRIC ACID; ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ABORTION; ANTICONVULSANT THERAPY; CONGENITAL MALFORMATION; DRUG BLOOD LEVEL; DRUG METABOLISM; EPILEPSY; FETUS; FETUS MALFORMATION; GESTATIONAL AGE; HUMAN; PREGNANCY; REVIEW; SEIZURE; TERATOGENICITY; TOXICITY TESTING;

ABNORMALITIES, DRUG-INDUCED; ANTICONVULSANTS; EPILEPSY; EUROPE; FEMALE; FETUS; HUMANS; IATROGENIC DISEASE; MULTICENTER STUDIES; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PRENATAL EXPOSURE DELAYED EFFECTS; TERATOGENS;

EID: 0036764338     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Meadow SR. Anticonvulsivants drugs and congenital abnormalities. Lancet 1968; 2: 1296.
2. Morrel MJ. The new antiepileptic drugs and women efficacy, reproductive health, pregnancy and fetal outcome. Epilepsia 1996; 37 (Suppl): S34-44.
3. Pita E. Antiepilépticos y embarazo. In Forcadas MI, Martínez M, coords. Epilepsia y Mujer. Grupo de Estudio de la Epilepsia. Sociedad Española de Neurología. Barcelona: Sanofi; 1998.
4. Yerbi MS, Field MN, McCornick C, Sells CJ. Pharmacokinetics of anticonvulsivants in pregnancy: Alterations in plasma protein binding. Epilepsy Res 1990; 5: 223-8.
5. Martínez M. Malformaciones y lesiones fetales en las embarazadas epilépticas. In Forcadas MI, Martínez M, coords. Epilepsia y Mujer. Grupo de Estudio de la Epilepsia. Sociedad Española de Neurología. Barcelona: Sanofi; 1998.
6. Shuster EA. Epilepsy in women. Mayo Clinic Proc 1996; 71: 991-9.
7. Fonager KM, Larsen H, Pedersen L, Sorensen HT. Congenital malformations and fetal growth of children with intrauterine exposure to anticonvulsivants. Ugeskr Laeger 2001; 163: 6279-283.
8. Koch S, Titze K, Zimmerman RB, Schroder M, Lehmkuhl U, et al. Long term neuropsychological consequences of maternal epilepsy and anticonvulsivant treatment during pregnancy for school-age children and adolescents. Epilepsia 1999; 40: 1237-43.
9. Arpino C, Brescianini S, Robert E, Cartilla E, Cocchi G, Cornel M, et al. Teratogenic effects of antiepileptic drugs: Use of an international Database on Malformations and Drug Exposure (MADRE). Epilepsia 2000; 41: 1436-43.
10. Kaneko S, Battino D, Anderman E, Wada IC, Kan IL, Takeda A, et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999; 33: 145-58.
11. Nau H, Tzimas G, Mondry M, Plum C, Sporh HL. Antiepileptic drugs alter endogenous retinoid concentrations: A possible mechanism of teratogenesis of anticonvulsivant therapy. Life Sci 1995; 57: 53-60.
12. Lampen A, Gottlicher M, Nau H. Prediction of embryotoxic effects of valproic acid derivates with molecular in vitro methods. Altex 2001; 18: 123-6.
13. Di Liberti JH, Farndon PA, Dennis NR, Curry CJR. The fetal valproate syndrome. Am J Med Genet 1984; 19: 473-81.
14. Ardinger H, Atkin J, Blackston RP, Elras IJ, Clarren SK, Livingstone S, et al. Verification of the fetal valproate syndrome phenotype. Am J Med Genet 1988; 29: 171-85.
15. Janas MS, Arroe M, Hansen SH, Graem L. Hypoplasia: A possible teratogenic effect of valproate. APMIS 1998; 106: 300-4.
16. Gardner RJ, Savarirayan R, Dunne KB, McLellan JA, Coleman LT, Suthers GK, et al. Microlissencephaly with cardiac, spinal and urogenital defects. Clin Dysmorphol 2001; 10: 203-8.
17. Williams G, Cunningham J, Stephan M, Kerr B, Hersh J. Fetal valproate syndrome and autism: Additional evidence of an association. Dev Med Child Neurol 2001; 43: 202-6.
18. Assencio-Ferreira VJ, Abraham R, Veiga JC, Santos KC. Metopic suture craniosynostosis: Sodium valproate teratogenic effect. Arq Neuropsiquiatr 2001; 59: 417-20.
19. Ozkinay F, Yenigun A, Kantar M, Ozkinay C, Amenoglu A, Ulman I, et al. Two siblings with fetal hydantoin syndrome. Turk J Pediatr 1998; 40: 273-8.
20. Sutcliffe AG, Jones RB, Woodruff G. Eye malformations associated with treatment with carbamazepine during pregnancy. Ophthalmic Genet 1998; 19: 59-62.
21. Titze K, Koch S, Lehmkul U, Rauh H. Socio familial epilepsy specific stress on women with epilepsy. Nervenarzt 2001; 72: 529-34.
22. Orup HI, Keith DA, Holmes LB. Prenatal anticonvulsivant drug exposure: Teratogenic effect on the dentition. J Craniofac Genet Dev Biol 1998; 18: 129-37.
23. Battino D. Are new AEDs teratogenic? Update from pregnancy registries. Epilepsia 2000; 41 (Suppl): S211-3.
24. Hoyme HE, Hauck L, Quinn D. Minor anomalies accompanying prenatal exposure of topiramate. J Invest Med 1998; 46: 119A.
25. Öhman I, Vitosl S, Söderfeldt B, Tonmson T. Pharmacokinetics of Topiramate in Pregnancy and Lactation-Transplacental Transferand Excretion in Breast-Milk. V Eilat Conference on New Antiepileptic Drugs. Eilat, Israel, 2000.
26. Sander JWAS, Patsalos PN. An assessment of serum and red blood cell folate concentrations in patients with epilepsy on lamotrigine therapy. Epilepsy Res 1992; 13: 89-92.
27. Quattrini A, Ortenzi A, Paggi A, Foschi N, Quattrini C. Lamotrigine and pregnancy. Ital J Neurol Sci 1996; 17: 441-2.
28. International Lamotrigine Pregnancy Registry. Interim Report. 1 September 1992-31 March 2001. Glaxo Wellcome Inc.
29. Mackay FJ, Wilton LV, Pearce GL, Freemantle SN, Mann RD, et al. Safety of long-term lamotrigine in epilepsy. Epilepsia 1997; 38: 881-6.
30. Tomson T, Ohman I, Vitols S. Lamotrigine in pregnancy and lactation: A case report. Epilepsia 1997; 38: 1039-41.
31. Öhman I, Vitols S, Tomson T. Lamotrigine in pregnancy: Pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia 2000; 41: 709-13.
32. Berry DJ. The disposition of lamotrigine throughout pregnancy. Ther Drug Monit 1999; 21: 450.
33. Sathanandar ST, Blesi K, Tran TA. Lamotrigine clearance increases markedly during pregnancy. Epilepsia 2000; 41 (Suppl 7): S246.
34. Lilly CL, Kaplan-Machlis B. Lamotrigine use in pregnancy. J Pharm Technol 1999; 15: 75-8.
35. Jovic NJ. Lamotrigine (LTG) in the treatment of pregnant patients with juvenile myoclonic epilepsy. Epilepsia 1999; 40 (Suppl) 2: S283.
36. Robinson CP. Gabapentin. Drugs Today 1994; 30: 451-5.
37. Genton P, van Vleymen BB. Piracetam and levetiracetam: Close structural similarities but different pharmacological and clinical profiles. Epileptic Disord 2000; 2: 99-105.
38. French J. Use levetiracetam in special situations. Epilepsia 2001; 42 (Suppl 4): 40-3.
39. Spiegelstein O, Moaha NE, Isoherranen N, Finnell RH, Roedu M, Jagen B, et al. Teratogenicity of Levetiracetam and Its Enantiomer R Alfa-Ethyl-Oxo-Pyrrolidine Acetamide in Mice. Communication at the American Epilepsy Society. December, 2001.
40. Kondo T, Kaneko S, Amano Yegawa I. Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy. Epilepsia 1996; 37: 1242-4.
41. Collins S, Donelly J, Krupa D. Pregnancy and TGB exposure. In 49th Annual Meeting American Academy of Neurology. Boston, 1997.
42. Adkins JC, Noble S. Tiagabine. Drugs 1998; 55: 437-60.
43. Abdulrazzaq YM, Padmanabhan R, Bastaki SM. Placental transfer of vigabatrin and its effect on concentration of amino acids in embryo of TO mice. Teratology 2001; 94: 304-22.
44. Battino D, Mamoli D, Messina S, Perucca E, Tomson T. Malformaciones en los hijos de embarazadas con epilepsia. Presentación de un registro internacional de fármacos antiepilépticos y embarazo (EURAP). I Congreso de la LECE. Bilbao. Rev Neurol 2001; (Suppl.): 77-81.
45. Guerra O, Oliveira LE, Peters VM. Pre-embryo development in rats treated with oxcarbazepine in first four days after insemination. Rev Assoc Med Bras 2000; 46: 346-53.
46. Pienimaki P, Lampela E, Hakkola J, Arvela P, Raunio H, Vahakangas K. Pharmacokinetics of OCBZ and CBZ in human placenta. Epilepsia 1997; 38: 309-16.
47. Beghi E, Annegers J. Pregnancy registries in epilepsy. Epilepsia 2001; 42: 1422-5.
48. Peña P. EURAP. I Congreso de la LECE. Bilbao. Rev Neurol 2001 (Suppl.): 72.
49. Martínez Ferri M. Atención a la mujer epiléptica. I Congreso de la LECE. Bilbao. Rev Neurol 2001 (Suppl.): 72-77.
50. Battino D. Assessment of teratogenic risk. Epilepsy Res 2001; 45: 171-3.
51. Malone FD, D'Alton ME. Drugs in pregnancy: Anticonvulsivants. Semin Perinatol 1997; 21: 114-23.
52. Nakken KO, Johannessen SI, Henriksen O. Epilepsy and pregnancy. Tidsskr Nor Laegeforen 1999; 119: 3437-40.
53. Crawford P. CCPD education and self-assessment: Epilepsy and pregnancy. Seizure 2001; 10: 212-9.